Biomarkers reduce the attrition rate of late-stage clinical trials by
assessing drug potential in terms of efficacy and toxicity at the early
stages of clinical development. Thus, biomarkers significantly increase
productivity, lower the cost and duration of clinical trials, and help
researchers complete the drug development process at a faster pace.
Scope of this research
- Assessment of the revenues of late-stage biomarker technology
and services in North America, Europe, Asia and the rest of the world.
- Details of the key market drivers and restraints in the biomarker sector.
- Information about microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services.
- Patent analysis with respect to competitors and geography.
- Discussion of major pharmaceutical companies, biotechs, contract research organizations and biomarker specialists.
Research and analysis highlights
The pharmaceutical and biotech sectors are currently facing
increasing duration and cost issues related to clinical trials in drug
discovery. Funding from government sources such as the National
Institutes of Health has not increased significantly over the last few
More than 50% of clinical trials fail in Phase III for a host of
reasons, including greater disease complexity, stiffer clinical
endpoints, and the inability of the data to prove drug effectiveness.
Biomarkers play a crucial role in late-stage clinical trials by
acting as surrogate endpoints for patient monitoring and stratification.
Surrogate endpoints help measure treatment efficacy, and thus
facilitate significant cost reductions in the drug development process.
Key reasons to purchase this research
- Examine and evaluate the growth potential of emerging technologies.
- Understand biomarker activity in the clinical trials of leading market players.
- Gain knowledge about the relative importance of biomarker late-stage clinical trials technologies over the next five years.
- Determine the collaborations and partnerships of the major market players.